{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T06:34:30Z","timestamp":1780814070516,"version":"3.54.1"},"reference-count":16,"publisher":"BMJ","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"abstract":"<jats:p>In 1937, when diethylene glycol was used as a solvent in the preparation of a medicinal product, an elixir of sulfanilamide, resulting in deaths, public outcry hastened the promulgation of an act that had been in preparation in the USA for several years, but which had met with opposition from pharmaceutical companies. The 1938 Food, Drug, and Cosmetics Act, as it was known, gave greater powers to the then recently formed Food and Drug Administration (FDA) in regulating the contents of medicinal formulations. Nevertheless, although similar regulatory systems have since been established around the world, episodes of poisoning with diethylene glycol in pharmaceutical formulations, whether deliberately included adulteration or as a contaminant, continue to be reported, generally in developing countries, usually affecting children, and often causing deaths.<\/jats:p>","DOI":"10.1136\/bmj.q356","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T21:15:11Z","timestamp":1707513311000},"page":"q356","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["When I use a word . . . Medicines regulation\u2014diethylene glycol"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-655X","authenticated-orcid":false,"given":"Jeffrey K","family":"Aronson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"2024020918300490000_384.feb09_14.q356.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04710.x"},{"key":"2024020918300490000_384.feb09_14.q356.2","unstructured":"Aronson JK. Apothecaries. BMJ Blogs. 29 January 2016. https:\/\/blogs.bmj.com\/bmj\/2016\/01\/29\/jeffrey-aronson-when-i-use-a-word-apothecaries."},{"key":"2024020918300490000_384.feb09_14.q356.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p2391"},{"key":"2024020918300490000_384.feb09_14.q356.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p2603"},{"key":"2024020918300490000_384.feb09_14.q356.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5415"},{"key":"2024020918300490000_384.feb09_14.q356.6","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15497"},{"key":"2024020918300490000_384.feb09_14.q356.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.01.006"},{"key":"2024020918300490000_384.feb09_14.q356.8","unstructured":"Anonymous. Post-mortem. Time U.S. 1937 Dec 20. https:\/\/web.archive.org\/web\/20090403071709\/http:\/\/www.time.com\/time\/magazine\/article\/0,9171,758704,00.html."},{"key":"2024020918300490000_384.feb09_14.q356.9","unstructured":"US Congress. House Committee on Interstate and Foreign Commerce and Its Subcommittee on Public Health and Environment, 1974. A Brief Legislative History of the Food, Drug, and Cosmetic Act. Committee Print No. 14. Washington DC: US Government Printing Office, 1974: 1-4."},{"key":"2024020918300490000_384.feb09_14.q356.10","unstructured":"Senate and House of Representatives of the United States of America in Congress. Federal Food, Drug, and Cosmetic Act. 52 Stat. 75th Congress, 3rd session, Chapter 675, 25 June 1938: 1040-60. https:\/\/legisworks.org\/sal\/52\/stats\/STATUTE-52-Pg1040a.pdf."},{"key":"2024020918300490000_384.feb09_14.q356.11","unstructured":"US Supreme Court. United States v. Dotterweich 320 US 277 (1943). https:\/\/supreme.justia.com\/cases\/federal\/us\/320\/277\/case.html."},{"key":"2024020918300490000_384.feb09_14.q356.12","doi-asserted-by":"publisher","DOI":"10.1080\/15563650903086444"},{"key":"2024020918300490000_384.feb09_14.q356.13","doi-asserted-by":"publisher","DOI":"10.1057\/jphp.2009.2"},{"key":"2024020918300490000_384.feb09_14.q356.14","first-page":"532","article-title":"Legislative history of the Federal Food, Drug, and Cosmetic Act","volume":"1","author":"Kleinfeld","year":"1946","journal-title":"Food Drug Cosmet Law Q"},{"key":"2024020918300490000_384.feb09_14.q356.15","first-page":"548","article-title":"The Federal Food, Drug, and Cosmetic Act and the medical practitioner","volume":"29","author":"McEniry","year":"1974","journal-title":"Cosmetic Law Journal"},{"key":"2024020918300490000_384.feb09_14.q356.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1206652"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.q356","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.q356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T02:30:17Z","timestamp":1707532217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.q356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":16,"alternative-id":["10.1136\/bmj.q356"],"URL":"https:\/\/doi.org\/10.1136\/bmj.q356","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]}}}